Last updated on June 2019

Study To Evaluate the Efficacy Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies


Brief description of study

This study will be conducted to compare E2027 to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus (CIBIC-Plus) Caregiver Input in participants with dementia with Lewy bodies after 12 weeks of treatment.

Clinical Study Identifier: NCT03467152

Find a site near you

Start Over

Brain and Spine Center

Chandler, AZ United States
  Connect »

Syrentis Clinical Research

Santa Ana, CA United States
  Connect »

Compass Research-Bioclinica

Melbourne, FL United States
  Connect »

Compass Research-Bioclinica

Orlando, FL United States
  Connect »

Advanced Research Consultants, Inc.

Palm Beach Gardens, FL United States
  Connect »

Anchor Neuroscience

Pensacola, FL United States
  Connect »

Compass Research-Bioclinica

The Villages, FL United States
  Connect »

St. Agnes Medical Group

Catonsville, MD United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Columbia University

New York, NY United States
  Connect »

UNC Hospital

Chapel Hill, NC United States
  Connect »

Raleigh Neurology

Raleigh, NC United States
  Connect »

PMG Research of Winston-Salem, LLC

Winston-Salem, NC United States
  Connect »

University of Virginia Adult Neurology

Charlottesville, VA United States
  Connect »

Eisai Trial Site #2

Westerstede, Germany
  Connect »

Eisai Trial Site #5

Nishisonogigun, Japan
  Connect »

Eisai Trial Site #3

Kurashiki-shi, Japan
  Connect »

Eisai Trial Site #16

Sakai-ku, Sakai-shi, Japan
  Connect »

Fundacio ACE

Barcelona, Spain
  Connect »

Dementia Research Unit

Crowborough, United Kingdom
  Connect »

Kings College

London, United Kingdom
  Connect »

Cognition Health

London, United Kingdom
  Connect »

Newcastle General Hospital

Newcastle, United Kingdom
  Connect »